Abstract
P-Glycoprotein/MDR1 represents an important component of the blood brain barrier and contributes to multidrug resistance. We investigated two derivatives of the anti-malarial artemisinin, SM616 and GHP-AJM-3/23, concerning their ability to interact with P-glycoprotein. The ability of the two compounds to inhibit P-glycoprotein (P-gp) activity was examined in sensitive CCRF-CEM and P-gp over-expressing and multidrug-resistant CEM/ADR5000 cells as well as in porcine brain capillary endothelial cells (PBCEC) by means of calcein-AM assays. Verapamil as well-known P-gp inhibitor was used as control drug. CEM/ADR5000 cells exhibited cross-resistance to GHP-AJM-3/23, but slight collateral sensitivity to SM616. Furthermore, SM616 inhibited calcein efflux both in CEM/ADR5000 and PBCEC, whereas GHP-AJM-3/23 did only increase calcein fluorescence in PBCEC, but not CEM/ADR5000. This may be explained by the fact that CEM/ADR5000 only express P-gp but not other ATP-binding cassette transporters, whereas PBCEC are known to express several ABC transporters and calcein is transported by more than one ABC transporter. Hence, SM616 may be the more specific P-gp inhibitor. In conclusion, the collateral sensitivity of SM616 as well as the inhibition of calcein efflux in both CEM/ADR5000 cells and PBCEC indicate that this compound may be a promising P-gp inhibitor to treat cancer therapy and to overcome the blood brain barrier.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Li, Y.; Wu, Y. L. Curr. Med. Chem.2003, 10, 2197–2230.
Efferth, T.; Kaina, B. Crit. Rev. Toxicol.2010, 40, 405–421.
Sun, W. S.; Han, J. X.; Yang, W. Y.; Deng, D. A.; Yue, X. F. Acta Pharmacol. Sin.1992, 13, 541–543.
Woerdenbag, H. J.; Moskal, T. A.; Pras, N.; Malingre, T. M.; el-Feraly, F. S.; Kampinga, H. H.; Konings, A. W. J. Nat. Prod.1993, 56, 845–849.
Zheng, G. Q. Planta Med.1994, 60, 54–57.
Beekman, A. C.; Woerdenbag, H. J.; van Uden, W.; Pras, N.; Konings, A. W.; Wikstrom, H. V. J. Pharm. Pharmacol.1997, 49, 1254–1258.
Efferth, T.; Rücker, G.; Falkenberg, M.; Manns, D.; Olbrich, A.; Fabry, U.; Osieka, R. Arzneimittelforschung1996, 46, 196–200.
Efferth, T.; Dunstan, H.; Sauerbrey, A.; Miyachi, H.; Chitambar, C. R. Int. J. Oncol.2001, 18, 767–773.
Efferth, T.; Sauerbrey, A.; Olbrich, A.; Gebhart, E.; Rauch, P.; Weber, H. O.; Hengstler, J. G.; Halatsch, M. E.; Volm, M.; Tew, K. D.; Ross, D. D.; Funk, J. O. Mol. Pharmacol.2003, 64, 382–394.
Steinbrück, L.; Pereira, G.; Efferth, T. Cancer Genomics Proteomics2010, 7, 337–346.
Sertel, S.; Eichhorn, T.; Sieber, S.; Sauer, A.; Weiss, J.; Plinkert, P. K.; Efferth, T. Chem. Biol. Interact.2010a, 185,42–52.
Sertel, S.; Eichhorn, T.; Simon, C. H.; Plinkert, P. K.; Johnson, S. W.; Efferth, T. Molecules2010b, 15, 2886–2910.
Efferth, T.; Giaisi, M.; Merling, A.; Krammer, P. H.; Li-Weber, M. PLoS One2007, 2, e693.
Dell’Eva, R.; Pfeffer, U.; Vené, R.; Anfosso, L.; Forlani, A.; Albini, A.; Efferth, T. Biochem. Pharmacol.2004, 68, 2359–2366.
Anfosso, L.; Efferth, T.; Albini, A.; Pfeffer, U. Pharmacogenomics J.2006, 6, 269–278.
Soomro, S.; Langenberg, T.; Mahringer, A.; Konkimalla, V. B.; Horwedel, C.; Holenya, P.; Brand, A.; Cetin, C.; Fricker, G.; Dewerchin, M.; Carmeliet, P.; Conway, E. M.; Jansen, H.; Efferth, T. J. Cell Mol. Med.2011, 15, 1122–1135.
Rasheed, S. A.; Efferth, T.; Asangani, I. A.; Allgayer, H. Int. J. Cancer2010, 127, 1475–1485.
Li, P. C.; Lam, E.; Roos, W. P.; Zdzienicka, M. Z.; Kaina, B.; Efferth, T. Cancer Res.2008, 68, 4347–4351.
Berdelle, N.; Nikolova, T.; Quiros, S.; Efferth, T.; Kaina, B. Mol. Cancer Ther.2011 [Epub ahead of print].
Efferth, T.; Briehl, M. M.; Tome, M. E. Int. J. Oncol.2003, 23, 1231–1235.
Efferth, T; Oesch, F. Biochem. Pharmacol.2004, 68, 3–10.
Efferth, T.; Volm, M. In Vivo2005, 19, 225–232.
Efferth, T.; Benakis, A.; Romero, M. R.; Tomicic, M.; Rauh, R.; Steinbach, D.; Häfer, R.; Stamminger, T.; Oesch, F.; Kaina, B.; Marschall, M. Free Radic. Biol. Med.2004, 37, 998–1009.
Kelter, G.; Steinbach, D.; Konkimalla, V. B.; Tahara, T.; Taketani, S.; Fiebig, H. H.; Efferth, T. PLoS One2007, 2, e798.
Efferth, T.; Ramirez, T.; Gebhart, E.; Halatsch, M. E. Biochem. Pharmacol.2004, 67, 1689–1700.
Konkimalla, V. B.; McCubrey, J. A.; Efferth, T. Curr. Cancer Drug Targets2009, 9, 72–80.
Bachmeier, B.; Fichtner, I.; Killian, P. H.; Kronski, E.; Pfeffer, U.; Efferth, T. PLoS One2011, 6, e20550.
Price, R.; van Vugt, M.; Nosten, F.; Luxemburger, C.; Brockman, A.; Phaipun, L.; Chongsuphajaisiddhi, T.; White, N. Am. J. Trop. Med. Hyg.1998, 59, 883–888.
Efferth, T.; Davey, M.; Olbrich, A.; Rücker, G.; Gebhart, E.; Davey, R. Blood Cells Mol. Dis.2002, 28, 160–168.
Efferth, T. Curr. Mol. Med.2001, 1, 45–65.
Gillet, J. P.; Efferth, T.; Remacle, J. Biochim. Biophys. Acta2007, 1775, 237–262.
Eichhorn, T.; Efferth, T. J. Ethnopharmacol.2011 [Epub ahead of print].
Bauer, B.; Miller, D. S.; Fricker, G.; Pharm. Res.2003, 20, 1170–1176.
Kimmig, A.; Gekeler, V.; Neumann, M.; Frese, G.; Handgretinger, R.; Kardos, G.; Diddens, H.; Niethammer, D. Cancer Res.1990, 50, 6793–6799.
Gillet, J. P.; Efferth, T.; Steinbach, D.; Hamels, J.; de Longueville, F.; Bertholet, V.; Remacle, J. Cancer Res.2004, 64, 8987–8993.
Gottesman, M. M.; Pastan, I. Annu. Rev. Biochem.1993, 62, 385–427.
Rautio, J.; Humphreys, J. E.; Webster, L. O. Drug Metab. Dispos.2006, 34, 786–792.
Szybalski, W.; Bryson, V. J. Bacteriol.1952, 64, 489–499.
Hall, M. D.; Handley, M. D.; Gottesman, M. M. Trends Pharmacol. Sci.2009, 30, 546–556.
Schinkel, A. H.; Wagenaar, E.; Mol, C. A.; van Deemter, L. J. Clin. Invest.1996, 97, 2517–2524.
Ayesh, S.; Shao, Y. M.; Stein, W. D. Biochim. Biophys. Acta1996, 1316, 8–18.
Borgnia, M. J.; Eytan, G. D.; Assaraf, Y. G. J. Biol. Chem.1996, 271, 3163–3171.
Safa, A. R. Curr. Med. Chem. Anticancer Agents2004, 4, 1–17.
Globisch, C.; Pajeva, I. K.; Wiese, M. Chem. Med. Chem.2008, 3, 280–295.
Shapiro, A. B.; Ling, V. Eur. J. Biochem.1997, 250, 122–129.
Mahringer, A.; Karamustafa, S.; Klotz, D.; Kahl, S.; Konkimalla, V. B.; Wang, Y.; Wang, J.; Liu, H. Y.; Boechzelt, H.; Hao, X.; Bauer, R.; Fricker, G.; Efferth, T. Cancer Genomics Proteomics2010, 7, 191–205.
Török, M.; Huwyler, J.; Gutmann, H.; Fricker, G.; Drewe, J. Exp. Brain Res.2003, 153, 356–365.
Stark, M.; Rothem, L.; Jansen, G.; Scheffer, G. L.; Goldman, I. D.; Assaraf, Y. G. Mol. Pharmacol.2003, 64, 220–227.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Steglich, B., Mahringer, A., Li, Y. et al. Inhibition of P-glycoprotein by two artemisinin derivatives. Nat. Prod. Bioprospect. 2, 59–64 (2012). https://doi.org/10.1007/s13659-012-0006-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13659-012-0006-3